Related Experiment Videos
DSCG eye drops in allergic rhino-conjunctivitis.
Acta Oto-Laryngologica. Supplementum
|January 1, 1979
Summary
Eye drops with 2% disodium cromoglycate (DSCG) significantly improved allergic rhinoconjunctivitis symptoms compared to placebo. DSCG eye drops offer a valuable new treatment option for seasonal allergies.
Area of Science:
- Ophthalmology
- Allergology
- Pharmacology
Background:
- Allergic rhinoconjunctivitis is a common condition affecting the eyes and nose.
- Current treatments may have limitations or side effects.
- Disodium cromoglycate (DSCG) is an established mast cell stabilizer.
Purpose of the Study:
- To evaluate the efficacy of 2% disodium cromoglycate (DSCG) eye drops.
- To assess DSCG as a treatment for allergic rhinoconjunctivitis during pollen season.
Main Methods:
- A randomized, placebo-controlled trial was conducted.
- Thirty patients with allergic rhinoconjunctivitis participated.
- Patients received either 2% DSCG eye drops or a placebo.
Main Results:
- A statistically significant improvement was observed in the DSCG treatment group.
- DSCG eye drops demonstrated superior efficacy compared to placebo.
- The difference in outcomes between active and placebo groups was statistically significant.
Conclusions:
- 2% DSCG eye drops are effective in managing allergic rhinoconjunctivitis.
- DSCG eye drops represent a valuable addition to existing treatment options.
- This study supports the use of DSCG for seasonal allergic eye and nasal symptoms.